ArticleBMC medical informatics and decision making2026
Explainable machine learning for the prediction of Alzheimer's disease-related cognitive impairment: a consensus feature selection approach.
Article in BMC medical informatics and decision making, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Explainable machine learning for predicting venous thromboembolism in septic shock patients.Frontiers in immunology · 2026Article
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly identification of Alzheimer's disease-related cognitive impairment remains challenging, and existing machine learning (ML) models often suffer from feature instability and limited interpretability. This study developed robust and explainable ML models using cerebrospinal fluid (CSF) biomarkers by systematically comparing sparsity-based (LASSO), importance-based (Boruta), and consensus feature selection strategies.
methodsA publicly available cohort of 333 individuals (91 cognitively impaired, 242 cognitively normal) was analyzed. Data were split into training (70%) and independent test (30%) sets. Multiple classifiers, including Elastic Net-regularized logistic regression (LR), support vector machine (SVM), random forest, XGBoost, and Naive Bayes (NB), were trained using repeated 5-fold cross-validation (10 repetitions; 10 × 5-fold cross-validation) with class weighting. Model performance was evaluated using discrimination, calibration, and clinical utility metrics, and interpretability was assessed using SHAP.
resultsAll models demonstrated strong discriminative performance on the test set (AUROC 0.861-0.958). LASSO-based models showed high specificity, Boruta-based models achieved higher sensitivity, and consensus-based models provided the most balanced performance. The consensus-LR and -SVM models achieved AUROC values of 0.954 and 0.951, respectively. Beyond discrimination, the consensus-LR model demonstrated good calibration and consistent net clinical benefit in decision curve analysis, analyses that remain relatively underreported in the Alzheimer's disease machine learning literature. SHAP analyses highlighted biologically plausible contributions from key biomarkers, including tau, Aβ42, NT-proBNP, pancreatic polypeptide, and IL-7.
conclusionsIn summary, stable and interpretable ML models for Alzheimer's disease-related cognitive impairment can be developed using CSF-derived biomarkers obtained through lumbar puncture. The proposed consensus-based feature selection framework improves feature stability and model transparency, facilitating the discrimination between cognitively normal and impaired individuals and providing a foundation for future external validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.